ThesisMirum Pharmaceuticals: the setup is constructive — LIVMARLI quarterly prescription volume and net revenue per patient (tracking penetration of ~600 diagnosed ALGS patients…
growth - The stock attracts biotech growth investors focused on commercial-stage rare disease companies approaching profitability…
Rising rates create moderate valuation pressure on pre-profitable biotech stocks as investors discount future cash flows more heavily…
Watch on earnings: LIVMARLI quarterly net revenue and sequential growth trajectory toward $400M+ annual run rate, Patient enrollment numbers and prescriber base expansion (tracking penetration of ~600 US ALGS patients), Operating cash burn rate and quarters of cash runway remaining.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $698M to $817M as livmarli quarterly prescription volume and net revenue per patient (tracking penetration of ~600 diagnosed algs patients.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
